机构持仓方面，截止2025年9月30日，安旭生物十大流通股东中，广发价值核心混合A（010377）位居 第五大流通股东，持股356.45万股，相比上期增加54.98万股。招商景气优选股票A（009864）位居第八 大流通股东，持股60.00万股，持股数量较上期不变。博时凤凰领航混合A（013450）退出十大流通股东 之列。 融券方面，安旭生物11月11日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00 元；融券余量0.00股，融券余额0.00元，超过近一年90%分位水平，处于高位。 责任编辑：小浪快报 11月11日，安旭生物涨4.39%，成交额9973.78万元。两融数据显示，当日安旭生物获融资买入额738.67 万元，融资偿还1137.35万元，融资净买入-398.67万元。截至11月11日，安旭生物融资融券余额合计 9448.65万元。 分红方面，安旭生物A股上市后累计派现8.95亿元。近三年，累计派现6.57亿元。 融资方面，安旭生物当日融资买入738.67万元。当前融资余额9448.65万元，占流通市值的1.75%，融资 余额低于近一年40%分位水平，处于较低位。 资料显示， ...

广发价值核心混合A（010377）成立日期2021年1月22日，最新规模40.9亿。今年以来收益62.87%，同 类排名441/8147；近一年收益57.13%，同类排名414/8056；成立以来亏损4.12%。 11月11日，安旭生物涨5.03%，截至发稿，报42.80元/股，成交3197.99万元，换手率0.61%，总市值 54.39亿元。 资料显示，杭州安旭生物科技股份有限公司位于浙江省杭州市莫干山路1418-50号4幢5层，成立日期 2008年7月4日，上市日期2021年11月18日，公司主营业务涉及POCT试剂及仪器的研发、生产与销售。 主营业务收入构成为：快速诊断试剂100.00%。 从安旭生物十大流通股东角度 数据显示，广发基金旗下1只基金位居安旭生物十大流通股东。广发价值核心混合A（010377）三季度 增持54.98万股，持有股数356.45万股，占流通股的比例为2.8%。根据测算，今日浮盈赚取约730.73万 元。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投 ...

Core Viewpoint - Anxu Bio experienced a 2.22% increase in stock price on November 6, with a trading volume of 55.2043 million yuan, indicating positive market sentiment despite a decline in revenue and net profit year-on-year [1][2]. Financing Summary - On November 6, Anxu Bio had a financing buy-in of 5.655 million yuan, with a net financing buy of 191,300 yuan, reflecting active trading [1]. - The total financing and securities balance reached 99.7456 million yuan, accounting for 1.92% of the circulating market value, which is above the 50th percentile level over the past year, indicating a relatively high financing level [1]. - There were no short-selling activities on November 6, with a short-selling balance of 0.00 yuan, placing it in the 90th percentile level over the past year, suggesting a lack of bearish sentiment [1]. Financial Performance - For the period from January to September 2025, Anxu Bio reported a revenue of 325 million yuan, a year-on-year decrease of 19.34%, and a net profit attributable to shareholders of 64.3586 million yuan, down 52.60% year-on-year [2]. - Since its A-share listing, Anxu Bio has distributed a total of 895 million yuan in dividends, with 657 million yuan distributed over the past three years [2]. Shareholder Structure - As of September 30, 2025, Anxu Bio had 6,090 shareholders, an increase of 1.10% from the previous period, while the average circulating shares per person decreased by 1.08% to 20,867 shares [2]. - Among the top ten circulating shareholders, Guangfa Value Core Mixed A ranked fifth with 3.5645 million shares, an increase of 549,800 shares from the previous period [2].

Core Insights - Anxu Bio, established in July 2008 and listed on the Shanghai Stock Exchange in November 2021, is a leading company in the domestic POCT reagent field, with a full industry chain advantage and high product quality and technology level [1] Financial Performance - For Q3 2025, Anxu Bio reported revenue of 325 million yuan, ranking 21st out of 39 in the industry, significantly lower than the top competitor's revenue of 3.428 billion yuan and the second competitor's 3.127 billion yuan, as well as below the industry average of 708 million yuan and median of 330 million yuan [2] - The company's net profit for the same period was 64.31 million yuan, ranking 14th in the industry, again far below the top competitor's net profit of 1.588 billion yuan and the second competitor's 1.205 billion yuan, but higher than the industry median of 26.19 million yuan and lower than the industry average of 110 million yuan [2] Financial Ratios - Anxu Bio's debt-to-asset ratio for Q3 2025 was 8.59%, down from 11.21% in the previous year and below the industry average of 18.29%, indicating strong solvency [3] - The gross profit margin for the same period was 40.82%, a decrease from 42.11% year-on-year and lower than the industry average of 56.20%, suggesting a need for improvement in profitability [3] Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 1.10% to 6,090, while the average number of circulating A-shares held per shareholder decreased by 1.08% to 20,900 [5] - Among the top ten circulating shareholders, Guangfa Value Core Mixed A ranked fifth with 3.5645 million shares, an increase of 549,800 shares from the previous period, while the eighth largest shareholder,招商景气优选股票A, held 600,000 shares, unchanged from the previous period [5]

Core Viewpoint - Anxu Bio experienced a slight increase in stock price and notable trading activity on September 25, 2023, with a focus on financing and stockholder data [1][2]. Group 1: Stock Performance and Trading Activity - On September 25, Anxu Bio's stock rose by 0.16%, with a trading volume of 17.95 million yuan [1]. - The financing buy-in amount for Anxu Bio on the same day was 4.54 million yuan, while the financing repayment was 2.36 million yuan, resulting in a net financing buy-in of 2.18 million yuan [1]. - As of September 25, the total financing and securities lending balance for Anxu Bio was 93.62 million yuan, which is 1.93% of its market capitalization and below the 50th percentile level over the past year, indicating a low financing balance [1]. Group 2: Securities Lending Activity - On September 25, Anxu Bio had no shares repaid or sold in securities lending, resulting in a sell amount of 0.00 yuan and a securities lending balance of 0.00 yuan, which is at a high level exceeding the 90th percentile over the past year [1]. Group 3: Financial Performance - For the first half of 2025, Anxu Bio reported a revenue of 230 million yuan, a year-on-year decrease of 7.42%, and a net profit attributable to shareholders of 59.31 million yuan, down 48.57% year-on-year [2]. - Since its A-share listing, Anxu Bio has distributed a total of 895 million yuan in dividends, with 657 million yuan distributed over the past three years [2]. Group 4: Shareholder Information - As of June 30, 2025, Anxu Bio had 6,024 shareholders, an increase of 1.50% from the previous period, with an average of 21,096 circulating shares per person, a decrease of 1.48% [2]. - Among the top ten circulating shareholders, Guangfa Value Core Mixed A held 3.01 million shares, unchanged from the previous period, while Zhaoshang Prosperity Preferred Stock A reduced its holdings by 10,000 shares to 600,000 shares [2].

Core Viewpoint - Anxu Bio experienced a decline in stock price and revenue, indicating potential challenges in its financial performance and market position [1][2]. Financing and Trading Activity - On August 27, Anxu Bio's stock fell by 2.70%, with a trading volume of 46.83 million yuan. The financing buy-in amounted to 15.09 million yuan, while financing repayment was 14.76 million yuan, resulting in a net financing buy of 0.33 million yuan [1]. - As of August 27, the total financing and securities lending balance for Anxu Bio was 97.20 million yuan, which represents 1.88% of its market capitalization. This financing balance is above the 60th percentile of the past year, indicating a relatively high level [1]. - In terms of securities lending, there were no shares repaid or sold on August 27, with a lending balance of 0.00 shares, placing it in the 90th percentile of the past year, also indicating a high level [1]. Financial Performance - As of June 30, Anxu Bio had 6,024 shareholders, an increase of 1.50% from the previous period. The average number of circulating shares per shareholder decreased by 1.48% to 21,096 shares [2]. - For the first half of 2025, Anxu Bio reported a revenue of 230 million yuan, a year-on-year decrease of 7.42%. The net profit attributable to shareholders was 59.31 million yuan, down 48.57% year-on-year [2]. - Since its A-share listing, Anxu Bio has distributed a total of 895 million yuan in dividends, with 657 million yuan distributed over the past three years [2]. Shareholder Composition - As of June 30, 2025, among the top ten circulating shareholders, Guangfa Value Core Mixed A held 3.01 million shares, unchanged from the previous period. Meanwhile,招商景气优选股票A reduced its holdings by 10,000 shares to 600,000 shares, and博时凤凰领航混合A entered the list as a new shareholder with 528,900 shares [2].

Core Insights - Anxu Biotech's stock increased by 0.86% on August 25, with a trading volume of 38.6154 million yuan [1] - The company reported a financing net purchase of 1.5327 million yuan on the same day, with a total financing balance of 96.5234 million yuan, representing 1.79% of its market capitalization [1] - For the first half of 2025, Anxu Biotech's revenue was 230 million yuan, a year-on-year decrease of 7.42%, and the net profit attributable to shareholders was 59.3059 million yuan, down 48.57% year-on-year [2] Financing and Trading Activity - On August 25, Anxu Biotech had a financing buy amount of 8.0656 million yuan and a financing repayment of 6.5328 million yuan, resulting in a net financing purchase of 1.5327 million yuan [1] - The total financing and securities lending balance was 96.5234 million yuan, which is above the 50th percentile level for the past year, indicating a high level of financing activity [1] - There were no securities lent or sold on August 25, with the securities lending balance also at zero, indicating a lack of short-selling activity [1] Shareholder and Dividend Information - As of June 30, 2025, Anxu Biotech had 6,024 shareholders, an increase of 1.5% from the previous period, while the average number of circulating shares per shareholder decreased by 1.48% to 21,096 shares [2] - The company has distributed a total of 895 million yuan in dividends since its A-share listing, with 657 million yuan distributed over the past three years [2] - Notable institutional shareholders include GF Value Core Mixed Fund and others, with some changes in holdings reported [2]

Core Viewpoint - The company reported a resilient performance in the first half of 2025, achieving revenue of 230 million yuan and a non-net profit of 23.59 million yuan, reflecting a year-on-year growth of 24.89% [1] Group 1: Financial Performance - The company achieved revenue of 230 million yuan in the first half of 2025 [1] - The non-net profit for the same period was 23.59 million yuan, representing a year-on-year increase of 24.89% [1] Group 2: Business Strategy - The company operates in the field of POCT (Point of Care Testing) reagents and instruments, focusing on research, production, and sales [1] - The company has adopted a "dual-wheel drive" strategy, maintaining operational resilience despite increasing uncertainties in overseas markets [1] - In the domestic market, the company has obtained multiple medical device registrations, including products for respiratory virus antigen testing and chest pain triage [1] - The company is expanding its C-end market through the "Anxu Ke" brand on e-commerce platforms, establishing a dual-track development model for B-end and C-end markets [1]

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Anxu Biological, which closed at 42.93 yuan with a PE ratio of 34.94 times, below the industry average of 56.56 times [1][2] - Anxu Biological's total market capitalization is 5.456 billion yuan, ranking 68th in the medical device industry based on PE ratio [1][2] - The company specializes in the research, production, and sales of POCT reagents and instruments, and has received multiple certifications including EU CE, Canadian, and Australian certifications [1] Group 2 - As of March 31, 2025, Anxu Biological had 5,935 shareholders, a decrease of 278 from the previous period, with an average holding value of 352,800 yuan per shareholder [1] - The latest quarterly report for Q1 2025 shows a revenue of 115 million yuan, a year-on-year decrease of 10.90%, and a net profit of 34.03 million yuan, down 51.52% year-on-year, with a gross margin of 42.32% [1]

Company Overview - Anxu Bio focuses on the research, development, production, and sales of POCT reagents and instruments [1] - The company has been recognized as a "Zhejiang Province Intellectual Property Demonstration Enterprise" and a "National Intellectual Property Advantage Enterprise" [1] - As of 2024, Anxu Bio has obtained 44 new authorized patents, including 13 invention patents, bringing the total to 305 authorized patents, of which 43 are invention patents [1] Financial Performance - As of the first quarter of 2025, Anxu Bio reported a revenue of 115 million yuan, a year-on-year decrease of 10.90% [1] - The net profit for the same period was approximately 34.03 million yuan, reflecting a year-on-year decline of 51.52% [1] - The company's gross profit margin stands at 42.32% [1] Market Position - Anxu Bio's current price-to-earnings (PE) ratio is 33.53, compared to the industry average of 54.56 and the industry median of 37.54 [2] - The company's total market capitalization is 5.235 billion yuan [1][2] - As of the first quarter of 2025, two institutions hold shares in Anxu Bio, with a total of 172,000 shares valued at 0.07 million yuan [1]